90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma | Zendy

Kevin C. Conlon | Zendy; Claude Sportès | Zendy; Martin W. Brechbiel | Zendy; Daniel H. Fowler | Zendy; Ronald E. Gress | Zendy; Miloš D. Miljković | Zendy; Clara C. Chen | Zendy; Millie Whatley | Zendy; Bonita R. Bryant | Zendy; Erin M. Corcoran | Zendy; Karen Kurdziel | Zendy; Stefania Pittaluga | Zendy; Chang H. Paik | Zendy; Jae Ho Lee | Zendy; Thomas A. Fleisher | Zendy; Jorge A. Carrasquillo | Zendy; Thomas A. Waldmann | Zendy

Open Access

⁹⁰Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma

Author(s) -

Kevin C. Conlon,

Claude Sportès,

Martin W. Brechbiel,

Daniel H. Fowler,

Ronald E. Gress,

Miloš D. Miljković,

Clara C. Chen,

Millie Whatley,

Bonita R. Bryant,

Erin M. Corcoran,

Karen Kurdziel,

Stefania Pittaluga,

Chang H. Paik,

Jae Ho Lee,

Thomas A. Fleisher,

Jorge A. Carrasquillo,

Thomas A. Waldmann

Publication year - 2020

Publication title -

cancer biotherapy and radiopharmaceuticals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.716

H-Index - 59

eISSN - 1557-8852

pISSN - 1084-9785

DOI - 10.1089/cbr.2019.3298

Subject(s) - daclizumab , medicine , carmustine , melphalan , etoposide , chemotherapy , oncology , cytarabine , autologous stem cell transplantation , transplantation , gastroenterology , tacrolimus

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research